PubRank

Kathryn Anastos

Author PubWeight™ 246.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
2 Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003 5.81
3 Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008 5.32
4 Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005 5.29
5 Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008 3.66
6 Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002 2.83
7 Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003 2.81
8 Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014 2.79
9 Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007 2.67
10 Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004 2.66
11 Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005 2.42
12 Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007 2.37
13 Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr 2002 2.30
14 Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health 2006 2.19
15 Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health 2002 2.15
16 Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002 2.11
17 Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med 2004 2.04
18 Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 2005 2.03
19 Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol 2007 2.00
20 Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010 2.00
21 The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011 1.94
22 Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 2004 1.94
23 Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010 1.87
24 Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005 1.86
25 Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011 1.80
26 Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003 1.78
27 Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 2009 1.73
28 Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr 2013 1.72
29 HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003 1.71
30 Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011 1.70
31 Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009 1.68
32 Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev 2007 1.67
33 Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2006 1.61
34 Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis 2002 1.59
35 Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004 1.58
36 Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol 2013 1.57
37 Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol 2005 1.53
38 Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004 1.50
39 Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study. AIDS 2013 1.43
40 Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr 2010 1.37
41 Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007 1.37
42 Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012 1.37
43 Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol 2010 1.36
44 Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2002 1.35
45 Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009 1.35
46 Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol 2014 1.32
47 Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005 1.31
48 Obesity and immune cell counts in women. Metabolism 2007 1.31
49 CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis 2003 1.29
50 Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend 2007 1.28
51 Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 2010 1.28
52 Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS 2004 1.21
53 Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS 2003 1.20
54 Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005 1.20
55 HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007 1.20
56 Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010 1.19
57 Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS 2004 1.18
58 Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS 2009 1.17
59 Impact of age on retention in care and viral suppression. J Acquir Immune Defic Syndr 2015 1.17
60 Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008 1.17
61 A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis 2012 1.17
62 Serum albumin is a powerful predictor of survival among HIV-1-infected women. J Acquir Immune Defic Syndr 2003 1.16
63 Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One 2013 1.16
64 The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr 2010 1.15
65 The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis 2011 1.13
66 Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009 1.10
67 HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study. J Clin Oncol 2010 1.09
68 Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis 2004 1.09
69 Predictors of reported influenza vaccination in HIV-infected women in the United States, 2006-2007 and 2007-2008 seasons. Prev Med 2010 1.08
70 Evolution and taxonomic classification of alphapapillomavirus 7 complete genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. PLoS One 2013 1.07
71 Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral Therapy: a Bayesian approach. J Virol 2004 1.06
72 Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS 2014 1.06
73 Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol 2005 1.06
74 Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA 2012 1.06
75 Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study. Antivir Ther 2010 1.04
76 Prevalence and predictors of posttraumatic stress disorder and depression in HIV-infected and at-risk Rwandan women. J Womens Health (Larchmt) 2009 1.04
77 Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol 2006 1.03
78 Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr 2012 1.03
79 Experience of pain among women with advanced HIV disease. AIDS Patient Care STDS 2009 1.02
80 Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy. Virology 2010 1.02
81 Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women. AIDS 2013 1.01
82 Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. AIDS 2015 1.01
83 Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 2005 1.01
84 Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study. Atherosclerosis 2012 1.01
85 Urinary markers of kidney injury and kidney function decline in HIV-infected women. J Acquir Immune Defic Syndr 2012 1.01
86 Pre-existing albuminuria predicts AIDS and non-AIDS mortality in women initiating antiretroviral therapy. Antivir Ther 2011 1.01
87 Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr 2014 1.00
88 Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women. J Gen Virol 2005 1.00
89 Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril 2008 0.99
90 HPV testing for triage of HIV-infected women with papanicolaou smears read as atypical squamous cells of uncertain significance. J Womens Health (Larchmt) 2004 0.99
91 The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. J Acquir Immune Defic Syndr 2011 0.98
92 Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death. Am J Epidemiol 2009 0.98
93 Awareness of hepatitis C infection among women with and at risk for HIV. J Gen Intern Med 2007 0.98
94 Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2013 0.97
95 Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am J Pathol 2002 0.97
96 Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data. Virol J 2010 0.96
97 Oxidant stress in HIV-infected women from the Women's Interagency HIV Study. Antivir Ther 2009 0.96
98 Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women. J Womens Health (Larchmt) 2006 0.96
99 Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study. Fertil Steril 2012 0.96
100 HIV and recent illicit drug use interact to affect verbal memory in women. J Acquir Immune Defic Syndr 2013 0.95
101 CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women. AIDS Educ Prev 2009 0.95
102 Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis 2009 0.95
103 Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. J Acquir Immune Defic Syndr 2013 0.94
104 Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses 2008 0.94
105 Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004 0.94
106 HIV tropism and decreased risk of breast cancer. PLoS One 2010 0.94
107 Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2015 0.94
108 The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002 0.93
109 Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine. AIDS 2012 0.93
110 Single-pill regimens for HIV-1 infection. N Engl J Med 2014 0.92
111 Insulin resistance and cognition among HIV-infected and HIV-uninfected adult women: the Women's Interagency HIV Study. AIDS Res Hum Retroviruses 2011 0.92
112 Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. AIDS Res Hum Retroviruses 2009 0.92
113 Association of serum albumin with markers of nutritional status among HIV-infected and uninfected Rwandan women. PLoS One 2012 0.92
114 Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS 2013 0.92
115 Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstet Gynecol 2004 0.92
116 Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer. J Acquir Immune Defic Syndr 2014 0.91
117 Correlates of prevalent hypertension in a large cohort of HIV-infected women: Women's Interagency HIV Study. AIDS 2007 0.91
118 A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict Biol 2010 0.91
119 Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy. J Virol 2011 0.91
120 Does patient-provider racial/ethnic concordance influence ratings of trust in people with HIV infection? AIDS Behav 2007 0.91
121 Women in Rwanda: another world is possible. JAMA 2005 0.90
122 Assessment of haematological parameters in HIV-infected and uninfected Rwandan women: a cross-sectional study. BMJ Open 2012 0.90
123 Prevalence of kidney disease in HIV-infected and uninfected Rwandan women. PLoS One 2011 0.90
124 Arterial wave reflection in HIV-infected and HIV-uninfected Rwandan women. AIDS Res Hum Retroviruses 2009 0.90
125 Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertil Steril 2007 0.89
126 Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr 2008 0.89
127 The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2010 0.88
128 Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev 2008 0.88
129 The association of HIV status with bacterial vaginosis and vitamin D in the United States. J Womens Health (Larchmt) 2011 0.88
130 The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS 2008 0.87
131 Increased circulating interleukin-7 levels in HIV-1-infected women. J Acquir Immune Defic Syndr 2005 0.87
132 The association of perceived stress and verbal memory is greater in HIV-infected versus HIV-uninfected women. J Neurovirol 2015 0.87
133 Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women. Cancer Epidemiol Biomarkers Prev 2013 0.87
134 Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2012 0.86
135 Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS One 2012 0.86
136 Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women. PLoS One 2011 0.86
137 HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS 2014 0.86
138 Human immunodeficiency virus (HIV) modulates the associations between insulin resistance and cognition in the current combination antiretroviral therapy (cART) era: a study of the Women's Interagency HIV Study (WIHS). J Neurovirol 2015 0.85
139 Association of cutaneous anergy with human papillomavirus and cervical neoplasia in HIV-seropositive and seronegative women. AIDS 2007 0.85
140 Associations of insulin-like growth factor (IGF)-I and IGF-binding protein-3 with HIV disease progression in women. J Infect Dis 2008 0.85
141 Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J Acquir Immune Defic Syndr 2006 0.85
142 Aging and HIV infection. J Urban Health 2006 0.85
143 Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death. Am J Epidemiol 2012 0.84
144 The S40 residue in HIV-1 Gag p6 impacts local and distal budding determinants, revealing additional late domain activities. Retrovirology 2013 0.84
145 Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization. J Virol 2013 0.84
146 Incidence of tuberculin skin test conversion among HIV-infected and -uninfected women: results of a 6-year study. J Acquir Immune Defic Syndr 2006 0.83
147 Does HIV infection promote early kidney injury in women? Antivir Ther 2013 0.83
148 Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the women's interagency HIV study (WIHS). J Clin Endocrinol Metab 2013 0.82
149 Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010 0.82
150 T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHS. J Acquir Immune Defic Syndr 2014 0.82
151 Effect of HIV infection on body composition and fat distribution in Rwandan women. J Int Assoc Physicians AIDS Care (Chic) 2010 0.82
152 Decentralizing Maternity Services to Increase Skilled Attendance at Birth and Antenatal Care Utilization in Rural Rwanda: A Prospective Cohort Study. Matern Child Health J 2015 0.82
153 Highly active antiretroviral therapy reduces urinary albumin excretion in women with HIV infection. J Acquir Immune Defic Syndr 2008 0.82
154 Cervicovaginal human papillomavirus (HPV)-infection before and after hysterectomy: evidence of different tissue tropism for oncogenic and nononcogenic HPV types in a cohort of HIV-positive and HIV-negative women. Int J Cancer 2012 0.82
155 Depressive symptoms are increased in the early perimenopausal stage in ethnically diverse human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Menopause 2012 0.82
156 Gender-Related Risk Factors Improve Mortality Predictive Ability of VACS Index Among HIV-Infected Women. J Acquir Immune Defic Syndr 2015 0.81
157 Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1. AIDS Res Hum Retroviruses 2012 0.81
158 Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women. J Neurovirol 2011 0.81
159 Do HIV-positive women receive depression treatment that meets best practice guidelines? AIDS Behav 2014 0.81
160 Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women. Am J Reprod Immunol 2014 0.81
161 Hormonal contraception and metabolic outcomes in women with or at risk for HIV infection. J Acquir Immune Defic Syndr 2009 0.81
162 Association of pre-treatment nutritional status with change in CD4 count after antiretroviral therapy at 6, 12, and 24 months in Rwandan women. PLoS One 2011 0.81
163 Associations of HIV infection with insulin and glucose levels in antiretroviral-naive Rwandan women: a cross-sectional analysis. BMJ Open 2013 0.80
164 Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses 2008 0.80
165 Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr 2014 0.80
166 The association of HIV infection with left ventricular mass/hypertrophy. AIDS Res Hum Retroviruses 2009 0.79
167 Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women. AIDS Res Hum Retroviruses 2013 0.79
168 An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa. J Low Genit Tract Dis 2016 0.79
169 Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 2004 0.79
170 Structural determinants of food insufficiency, low dietary diversity and BMI: a cross-sectional study of HIV-infected and HIV-negative Rwandan women. BMJ Open 2012 0.79
171 Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women. AIDS Res Hum Retroviruses 2006 0.79
172 CCR2 genotype and disease progression in a treated population of HIV type 1-infected women. Clin Infect Dis 2004 0.79
173 Plasma homocysteine is not associated with HIV serostatus or antiretroviral therapy in women. J Acquir Immune Defic Syndr 2009 0.78
174 Single-nucleotide polymorphisms in TrkB and risk for depression: findings from the women's interagency HIV study. J Acquir Immune Defic Syndr 2013 0.78
175 Improvement in posttraumatic stress disorder in postconflict Rwandan women. J Womens Health (Larchmt) 2011 0.78
176 The relation of plasmacytoid dendritic cells (pDCs) and regulatory T-cells (Tregs) with HPV persistence in HIV-infected and HIV-uninfected women. Viral Immunol 2014 0.78
177 Anthropometric measures and cognition in middle-aged HIV-infected and uninfected women. The Women's Interagency HIV Study. J Neurovirol 2013 0.78
178 Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis 2012 0.78
179 Systemic Immune Activation and HIV Shedding in the Female Genital Tract. J Acquir Immune Defic Syndr 2016 0.77
180 Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women. J Acquir Immune Defic Syndr 2015 0.77
181 Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women. AIDS 2014 0.77
182 A novel denaturing heteroduplex tracking assay for genotypic prediction of HIV-1 tropism. J Virol Methods 2012 0.77
183 Evaluation of DNA adduction of AZT in peripheral blood leukocytes of HIV-infected individuals by (32)P-post-labeling thin-layer chromatography: a feasibility study. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.76
184 Molecular epidemiology of HIV type 1 subtypes in Rwanda. AIDS Res Hum Retroviruses 2013 0.76
185 Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr 2013 0.76
186 HIV serostatus differs by catechol-O-methyltransferase Val158Met genotype. AIDS 2013 0.76
187 Sexual Behavior and Risk Practices of HIV Positive and HIV Negative Rwandan Women. AIDS Behav 2015 0.76
188 Chronic depressive symptoms and Framingham coronary risk in HIV-infected and HIV-uninfected women. AIDS Care 2011 0.76
189 Effects of Antiretroviral Therapy and Depressive Symptoms on All-Cause Mortality Among HIV-Infected Women. Am J Epidemiol 2017 0.75
190 Definition of proteinuria among women with HIV infection. Kidney Int 2004 0.75
191 Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women. J Acquir Immune Defic Syndr 2016 0.75
192 The impact of HIV status, HIV disease progression, and post-traumatic stress symptoms on the health-related quality of life of Rwandan women genocide survivors. Qual Life Res 2012 0.75
193 Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women. AIDS Res Hum Retroviruses 2013 0.75
194 Good news for women living with HIV. J Infect Dis 2007 0.75
195 Hepatitis C viremia is associated with cytomegalovirus IgG antibody levels in HIV-infected women. PLoS One 2013 0.75
196 Association of markers of hemostasis with death in HIV-infected women. J Acquir Immune Defic Syndr 2014 0.75
197 Risk of breast cancer with CXCR4-using HIV defined by V3 loop sequencing. J Acquir Immune Defic Syndr 2015 0.75
198 Prevalence and Predictors of Hospitalizations Among HIV-Infected and At-Risk HIV-Uninfected Women. J Acquir Immune Defic Syndr 2017 0.75
199 Differences in the Nonuse of any Contraception and Use of Specific Contraceptive Methods in HIV Positive and HIV Negative Rwandan Women. AIDS Res Treat 2012 0.75
200 Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. J Acquir Immune Defic Syndr 2016 0.75
201 Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009. J Acquir Immune Defic Syndr 2016 0.75
202 Association of a 3' Untranslated Region Polymorphism in PCSK9 with HIV Viral Load and CD4+ Levels in HIV/Hepatitis C Virus Co-Infected Women. AIDS 2017 0.75
203 Vitamin A deficiency and genital viral burden in women infected with HIV-1. Lancet 2002 0.75
204 Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women. AIDS 2017 0.75
205 Perceived and post-traumatic stress are associated with decreased learning, memory, and fluency in HIV-infected women. AIDS 2017 0.75